Drugs Health Pharma

Pfizer’s blood cancer trial data shows survival of more than 2 years 

Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to.

Read More
Drugs Health Pharma

Genetic factors may help predict loss of X chromosome in older women

Researchers co-led by the US-based National Cancer Institute have found genetic variants in women that may play a role in promoting abnormal blood.

Read More
Drugs Health Pharma

GSK’s blood cancer test drug halves risk of disease progression: Data 

British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a.

Read More
Drugs Health Pharma

Johnson & Johnson’s blood cancer medicine cleared for bi-weekly use

HQ Team February 21, 2024: Johnson & Johnson announced that USFDA had approved a bi-weekly dose of its blood cancer therapy Tecvayli. The regulatory.

Read More
Drugs Health Pharma

Gilead Sciences puts last-stage blood cancer trials on hold after FDA order

HQ Team February 8, 2024: Gilead Sciences, Inc., announced it has discontinued trials on a drug to treat blood cancer after the US.

Read More
Drugs Health Pharma

Novartis to buy MorphoSys for $2.9 billion to expand cancer portfolio

HQ Team February 6, 2024: Novartis AG is set to buy a German-based biotechnology company, MorphoSys AG, for $2.9 billion, giving the Swiss.

Read More
Drugs Health Pharma

Eli Lilly’s drug gets second FDA nod for treating blood cancer in adults

HQ Team December 4, 2023: Eli Lilly and Company got a second accelerated approval from the Food and Drug Administration for its blood.

Read More
Drugs Health Pharma

US scientists zero in on single blood cancer therapy in animal studies

HQ Team September 28, 2023: US scientists have honed in on a single chimeric antigen receptor T-cell (CAR T) therapy to cure all.

Read More
Drugs Health Pharma

EMA recommends stopping sale of GSK’s blood cancer drug in EU

The European Medicines Agency has recommended the stoppage of conditional marketing authorisation for GSK’s Blenrep (belantamab mafodotin), a medicine used to treat cancer of.

Read More
Drugs Health Pharma

US regulator approves Pfizer’s Elrexfio to treat multiple myeloma

HQ Team August 15, 2023: The USFDA has granted accelerated approval for Pfizer Inc’s Elrexfio to treat incurable blood cancer, multiple myeloma, that.

Read More
X